GENE ONLINE|News &
Opinion
Blog

2019-03-04| Trials & Approvals

Herceptin Hylecta bags FDA approval for HER2-Positive Breast Cancer Treatment

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

This new formulation is ready-to-use and can be administered as a subcutaneous injection within two to five minutes, as opposed to its intravenous counterpart that takes 30-90 minutes.

Herceptin (Trastuzumab) is a monoclonal antibody used for the treatment of breast cancer in patients overexpressing the Human Epidermal growth factor Receptor 2 (HER2), which belongs to the family of four epidermal growth factor receptors. These tyrosine kinases are found to be upregulated in various types of cancers including breast cancer and aids in the growth and survival of tumors. Herceptin selectively binds to the HER2 receptor and prevents dimerization, thereby resulting in cell cycle arrest. Initially available only as an intravenous (IV) injection, trastuzumab effectively increased the survival rates of metastatic breast cancer patients when given in combination with chemotherapy agents such as paclitaxel. In recent years though, a new subcutaneous formulation became increasingly popular due to the ease of administration. Initially approved in Europe in the year 2013, it is now approved in as many as 100 countries.

 

USFDA Approval

At this juncture, on the 28th of February, the USFDA approved trastuzumab and hyaluronidase-oysk injection, for subcutaneous use in certain patients with HER2-positive breast cancer. This formulation uses the same monoclonal antibody as that of IV trastuzumab. The antibody is delivered subcutaneously with the help of an enzyme, the recombinant human hyaluronidase PH20 using the Enhanze drug delivery technology developed by Halozyme Therapeutics.

The approval is based on the encouraging results obtained from three clinical studies in HER2-positive early breast cancer patients;

  • The phase III HannaH study (NCT00950300)
  • The phase III SafeHER study (NCT01566721) and
  • The PrefHER trial (NCT01401166)

“Over the past 20 years, Herceptin has significantly advanced treatment of HER2-positive breast cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “The approval of Herceptin Hylecta gives physicians and patients in the United States a new option to select treatment based on individual needs and preferences.”

IV trustuzumab is commonly known to cause adverse effects in patients. Likewise, the patients receiving Herceptin Hylecta reported to have experienced tiredness, joint pain, diarrhea, injection site reaction, upper respiratory tract infection, rash, muscle pain, nausea, headache, swelling, flushing, fever, cough, and extremity pain. The recommended dose is 600 mg trastuzumab and 10,000 units hyaluronidase administered subcutaneously once every three weeks.

 

References
  1. https://www.roche.com/media/releases/med-cor-2019-02-28.htm
  2. https://www.onclive.com/web-exclusives/fda-approves-subcutaneous-trastuzumab-formulation-for-her2-breast-cancer
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506771/

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
The FDA Expands Use for Gilead Science’s HBV Treatment
2022-11-02
Santhera, ReveraGen’s Duchenne Drug Accepted By EMA While Anticipating FDA Priority Review
2022-11-01
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!